argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 50.31B +68.3% |
| Revenue (ttm) | 4.65B +70.3% |
| Net Income | 1.50B +33.9% |
| EPS | 22.95 +39.8% |
| Shares Out | 62.54M |
| PE Ratio | 35.06 |
| Forward PE | 28.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,986 |
| Open | 807.80 |
| Previous Close | 804.40 |
| Day's Range | 797.00 - 811.30 |
| 52-Week Range | 508.60 - 833.60 |
| Beta | -0.02 |
| Analysts | Buy |
| Price Target | 902.76 (+12.31%) |
| Earnings Date | Jul 23, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for ARGX stock is "Buy." The 12-month stock price target is €902.76, which is an increase of 12.31% from the latest price.
News
M&A News: Forte Biosciences Shares Leap 40% After Argenx Seals $2.2B Immunology Deal
Shares in Forte Biosciences ($FBRX) were 40% healthier in pre-market trading today after it was bought by peer Argenx ($ARGX) for $2.2 billion. Multiple Autoimmune Conditions Dutch immunology innovati...
argenx SE Press release: M&A announcement
argenx SE issued a press release on July 27, 2026, disclosing material business information to investors.
Argenx price target raised to $932 from $867 at Baird
Baird raised the firm’s price target on Argenx (ARGX) to $932 from $867 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results which…
Argenx to acquire Forte Biosciences for $77 per share in cash
Argenx (ARGX) and Forte (FBRX) announced that the companies have entered into a definitive agreement under which Argenx will acquire Forte Biosciences for $77 per share in cash, representing a…
Argenx To Acquire Forte For Approx. $2.2 Bln To Expand Immunology Pipeline; Forte Shares Soar
(RTTNews) - Argenx (ARGX), an immunology company, and Forte Biosciences, Inc. (FBRX),a clinical-stage biopharmaceutical company on Monday announced that they have entered into a definitive agreement u...
Argenx Acquires Forte Biosciences for $2.2 Billion, Expanding Pipeline
Argenx Acquires Forte Biosciences for $2.2 Billion, Expanding Pipeline
Argenx to Buy Forte Biosciences for $2.2 Billion
The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.
Argenx to buy Forte Biosciences for about $2.2 billion
Belgian-Dutch immunology company argenx will buy Forte Biosciences to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
Transaction builds on argenx's prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in v...
ARGX Maintains Rating by Oppenheimer -- Price Target Raised to $1037
ARGX Maintains Rating by Oppenheimer -- Price Target Raised to $1037
ARGX Maintained by RBC Capital -- Price Target Raised to $1025
ARGX Maintained by RBC Capital -- Price Target Raised to $1025
Argenx price target raised to $1,203 from $1,182 at Citi
Citi raised the firm’s price target on Argenx (ARGX) to $1,203 from $1,182 and keeps a Buy rating on the shares.
Argenx price target raised to $950 from $900 at Barclays
Barclays raised the firm’s price target on Argenx (ARGX) to $950 from $900 and keeps an Overweight rating on the shares.
ARGX Maintained by Guggenheim -- Price Target Raised to $1185
ARGX Maintained by Guggenheim -- Price Target Raised to $1185
ARGX Maintained by Citizens -- Price Target Lowered to $932
ARGX Maintained by Citizens -- Price Target Lowered to $932
Argenx price target raised to $1,200 from $1,180 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Argenx (ARGX) to $1,200 from $1,180 and keeps an Overweight rating on the shares after the company reported Q2 revenues “meaningfully above…
Argenx price target raised to $1,025 from $945 at RBC Capital
RBC Capital raised the firm’s price target on Argenx (ARGX) to $1,025 from $945 and keeps an Outperform rating on the shares after its Q2 results. Vyvgart was an impressive…
Argenx price target raised to $1,037 from $1,014 at Oppenheimer
Oppenheimer raised the firm’s price target on Argenx (ARGX) to $1,037 from $1,014 and keeps an Outperform rating on the shares. For Q2, Argenx delivered another strong quarter with $1.5B…
Argenx price target raised to $1,065 from $955 at Leerink
Leerink raised the firm’s price target on Argenx (ARGX) to $1,065 from $955 and keeps an Outperform rating on the shares.
Argenx price target raised to $1,185 from $1,135 at Guggenheim
Guggenheim raised the firm’s price target on Argenx (ARGX) to $1,185 from $1,135 and keeps a Buy rating on the shares. Global Vyvgart sales came in as “a clear beat”…
Argenx price target raised to $1,350 from $1,291 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,350 from $1,291 and keeps an Overweight rating on the shares. The firm says Vyvgart’s Q2 beat and management’s…
Argenx price target lowered to $932 from $944 at Citizens
Citizens lowered the firm’s price target on Argenx (ARGX) to $932 from $944 and keeps an Outperform rating on the shares. Argenx delivered stronger-than-expected Q2 results, with continued VYVGART gro...
Argenx price target raised to $1,025 from $945 at RBC Capital
RBC Capital raised the firm’s price target on Argenx (ARGX) to $1,025 from $945 and keeps an Outperform rating on the shares after the company reported Q2 results. Vyvgart was…
argenex Q2 Earnings Call Highlights
argenex NASDAQ: ARGX reported what executives described as one of its strongest quarters to date, driven by continued growth for VYVGART across myasthenia gravis and chronic inflammatory demyelinating...
argenx SE Earnings Call Transcript: Q2 2026
Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's strong performance in MG and CIDP, including the seronegative MG launch. Pipeline progress and label expansions are set to sustain long-term growth, with robust financials and disciplined capital allocation.